BOVINE VIRAL DIARRHEA VIRUS (BVDV) IN SWINE
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission; Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s); Moderate: Manageable losses related to endemic (population) or chronic (individual) occurrence; Negligible: Little or no market disruption when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); No availability: Effective vaccines not currently available in the US (or have not been developed); Not feasible: Eradication extremely unlikely
OVERVIEW
Bovine viral diarrhea virus (BVDV) is a pestivirus that primarily infects cattle but can cause cross-species infection in pigs. While natural BVDV infection of swine was first reported in Australia in 1964, it remains relatively uncommon compared to CSFV. BVDV infection of pigs is of primary concern because it can cause reproductive disease resembling congenital CSF and complicates CSFV control/eradication programs due to serological cross-reactions among pestiviruses. Postnatal BVDV infection in pigs is relatively nonpathogenic, producing only slight temperature elevation and transient leukopenia/thrombocytopenia. However, in utero infection of fetal piglets—particularly during the first trimester—can cause significant reproductive losses including poor conception rates, small litters, abortions, mummified fetuses, stillbirths, and weak piglets with congenital defects. Persistently infected, immunotolerant piglets can result from transplacental infection, similar to the well-documented BVDV persistent infection in cattle. These persistently infected pigs shed large amounts of virus and can transmit infection to susceptible pregnant sows, perpetuating disease in the herd. BVDV infection typically enters pig herds through contact with cattle (direct or via contaminated milk/whey fed to sows) or through contaminated biologicals including vaccines produced using bovine serum. The prevalence of BVDV antibodies in pig populations of CSFV-free countries ranges from 1.6-43.5%, depending on age and degree of cattle contact. Prevention focuses on avoiding contact with cattle and ensuring biologicals are free of pestivirus contamination.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
The chapter explicitly states that pestiviruses have "no evidence of human infection" and "are not of any significance for public health or food safety." BVDV, as a pestivirus, poses no foodborne risk to humans. Despite widespread global distribution in cattle populations and occasional spillover to other species including pigs, no human infections have been documented through any route including consumption of products from infected animals.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
BVDV does not infect humans. Veterinarians, farmers, and laboratory workers handling BVDV-infected cattle and other species have extensive occupational exposure without documented human infection. The virus poses no public health concern.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission
BVDV transmission to pigs occurs through identifiable, controllable pathways. Cattle are the primary source of infection, with transmission occurring via: direct contact with cattle (especially persistently infected animals); contaminated whey or milk fed to sows; contact with cattle recently vaccinated with modified live BVDV vaccines; and movement of personnel and equipment between cattle and pig units. Importantly, contaminated biologicals—particularly vaccines produced using bovine serum or secondary cell cultures—have caused outbreaks when administered to pregnant sows. Once BVDV enters a pig herd, the most significant amplification occurs through persistently infected piglets born to sows infected during early pregnancy. These persistently infected pigs shed large amounts of virus and rapidly infect in-contact animals (susceptible young animals placed in contact with congenitally infected piglets quickly seroconvert with high antibody titers). However, pigs infected postnatally do not appear to spread infection to in-contact animals, suggesting low or no virus excretion from pigs with transient infection. Standard biosecurity measures can effectively prevent BVDV introduction: avoiding direct or indirect contact with cattle; not feeding bovine milk products to pigs; ensuring all biologicals are certified pestivirus-free; and sourcing replacement animals from BVDV-free herds.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s)
Postnatal BVDV infection in pigs typically occurs without clinical signs, making detection challenging unless reproductive losses prompt investigation. When in utero infection causes reproductive disease, the clinical presentation can resemble congenital CSFV infection—necessitating laboratory differentiation. This is particularly important in CSFV-free countries where any pestivirus-related reproductive losses must be investigated to rule out CSFV. Laboratory diagnosis uses: real-time RT-PCR (preferred for RNA detection—rapid, sensitive, specific); pan-pestivirus assays can screen samples, with BVDV-specific assays confirming species; virus isolation in ruminant cell lines (BVDV from pigs replicates better in bovine than porcine cells); and serology showing pestivirus antibodies, with comparative virus neutralization testing against multiple pestiviruses (CSFV, BVDV, BDV) to identify the infecting species (threefold or greater difference in titers is considered conclusive). Suitable samples include tonsil, spleen, kidney, whole blood (EDTA), and fetal tissues. The main diagnostic challenge is the serological cross-reaction among pestiviruses, which requires differential testing to confirm BVDV (rather than CSFV or BDV) as the cause of infection—essential for CSFV surveillance programs.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Moderate: Manageable losses related to endemic (population) or chronic (individual) occurrence
BVDV infection in pigs is relatively uncommon and typically causes limited economic impact compared to CSFV or primary pig pathogens. Postnatal infection is essentially subclinical, with only transient mild effects (slight temperature increase, leukopenia/thrombocytopenia in some pigs). Economic losses occur primarily when pregnant sows are infected, causing: poor conception rates; small litters; abortions; mummified and stillborn pigs at farrowing. Clinical signs in piglets from affected litters include anemia, rough hair coats, growth retardation, wasting, congenital tremors, conjunctivitis, diarrhea, polyarthritis, petechiae, and blue ear tips. Mortality in affected litters at 2 days of age has ranged from 30-70% in documented outbreaks. However, disease occurrence depends on: (1) exposure of pregnant, susceptible sows to BVDV; (2) timing of infection during gestation (first trimester most severe); and (3) strain pathogenicity (some BVDV strains appear more pathogenic for pig fetuses than others—the Singer strain and BVDV strain 87/6 cause fetal mortality while the NADL strain does not). Given the relatively uncommon occurrence and the ability to prevent introduction through management practices, BVDV represents a manageable rather than catastrophic production risk for most pig operations.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Negligible: Little or no market disruption when disease occurs on one or more farms
BVDV infection of pigs is not a WOAH-listed condition and does not trigger trade restrictions. The primary concern is diagnostic confusion with CSFV during surveillance and eradication programs. In CSFV-free countries, detection of pestivirus antibodies in pigs requires differential testing to rule out CSFV—BVDV antibodies can cause false-positive reactions in CSFV serological assays, complicating surveillance. However, once BVDV (rather than CSFV) is confirmed as the cause, there are no regulatory or trade consequences. BVDV is endemic in cattle populations worldwide, so its occasional occurrence in pigs is not unexpected and does not affect market access. The economic impact is limited to direct production losses and the cost of diagnostic investigation, not trade disruption.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
BVDV is a viral pathogen (positive-sense single-stranded RNA pestivirus) that does not carry, acquire, or transmit antimicrobial resistance genes. The virus poses no AMR concerns. Genetic diversity exists within BVDV (at least 21 BVDV1 subgenotypes and 4 BVDV2 subgenotypes), representing viral evolution rather than antimicrobial resistance.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
No antiviral treatments exist for BVDV in any species. In pigs, postnatal infection is essentially subclinical and requires no treatment. When reproductive losses occur, the damage has already happened during fetal development and cannot be reversed. Antimicrobials might be used to address secondary bacterial infections in affected piglets, but this would represent rare, individual animal treatment. The primary management approach is prevention through biosecurity, not treatment.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
No specific treatments exist for BVDV infection in pigs or any other species. Postnatal infection in pigs is self-limiting and subclinical—pigs mount an immune response and clear the virus without intervention. Persistently infected piglets (immunotolerant from in utero infection) cannot clear the virus and serve as ongoing sources of infection; culling these animals removes the source. In utero damage causing reproductive losses and congenital defects cannot be reversed. Management focuses entirely on prevention.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: No availability: Effective vaccines not currently available in the US (or have not been developed)
No BVDV vaccines are licensed or used for pigs. The chapter notes: "There is little interest in establishing protection by vaccination in pigs against BVDV or BDV. Consequently, there has been little done to study the immune response of pigs to these viruses." Given the relatively uncommon occurrence of BVDV disease in pigs and the availability of effective prevention through biosecurity (avoiding cattle contact, ensuring pestivirus-free biologicals), vaccine development for swine is not a priority. Interestingly, experimental infection of pigs with BVDV or BDV can induce immunity that provides cross-protection against CSFV challenge—young pigs infected with BDV and later challenged with virulent CSFV were completely protected—demonstrating the immunological relationship among pestiviruses.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Not feasible: Eradication extremely unlikely
BVDV eradication from US pigs is not feasible as a standalone objective because: (1) BVDV is endemic in the US cattle population, providing an ongoing reservoir and source of exposure for pigs; (2) Cross-species transmission will continue as long as cattle and pigs have direct or indirect contact; (3) Bovine serum products used in biologicals can be contaminated with BVDV despite testing (the "HoBi" and related atypical pestiviruses have been detected in commercial fetal bovine serum, illustrating ongoing contamination risks). Eradicating BVDV from cattle populations is technically possible and has been achieved in some European countries (Scandinavia), but this would require a massive, coordinated, multi-year program far beyond current US priorities. For the swine industry, the practical approach is prevention and management: avoiding cattle contact, using certified pestivirus-free biologicals, and maintaining awareness of BVDV as a differential diagnosis for reproductive problems. Complete elimination of BVDV exposure risk for US pigs is not achievable while BVDV remains endemic in cattle.